Literature DB >> 8809140

CR1 stump peptide and terminal complement complexes are found in the glomeruli of lupus nephritis patients.

J E Teixeira1, R S Costa, P J Lachmann, R Würzner, J E Barbosa.   

Abstract

The number of CR1 on podocytes is reduced in nephropathies with severe glomerular damage, especially in the diffuse proliferative glomerulonephritis (DPGN) of systemic lupus erythematosus (SLE). Reduction of CR1 number on erythrocytes is due to proteolysis of CR1 by macrophage proteases activated by the reaction of their complement receptors, which leaves a 'CR1 stump peptide' on the erythrocyte. In the present study, we demonstrated the presence of the terminal complement complex (TCC) and the CR1 stump in histological sections of biopsies from patients with SLE by the indirect immunoperoxidase technique. Less severe glomerular lesions presented TCC deposits mainly in the mesangium (mesangial pattern). In lupus nephritis, with more severe glomerular damage, TCC deposits were detected both in the mesangium and in the capillary loops with podocyte involvement (mixed pattern). Patients with highly active DPGN presented a marked reduction of intact podocyte CR1 receptors in association with increased reactivity to the anti-CR1 stump antibody and with glomerular TCC deposits of mixed histological pattern. These results suggest that the decrease in the number of podocyte CR1 receptors in severe glomerular lesions of SLE may be due to a local proteolytic activity associated with activation and deposition of TCC.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8809140      PMCID: PMC2200531          DOI: 10.1046/j.1365-2249.1996.d01-776.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  10 in total

Review 1.  What has the immune system got against the glomerular podocyte?

Authors:  P W Mathieson
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

2.  Expression of complement receptor type 1 (CR1) on erythrocytes of paracoccidiodomycosis patients.

Authors:  J E Teixeira; R Martinez; L M Câmara; J E Barbosa
Journal:  Mycopathologia       Date:  2001       Impact factor: 2.574

Review 3.  Cross Talk between Mesenchymal Stem/Stromal Cells and Innate Immunocytes Concerning Lupus Disease.

Authors:  Mahmoud Mahmoudi; Akram Hoseinzadeh; Zahra Rezaieyazdi; Jalil Tavakol Afshari; Ali Mahmoudi; Sahar Heydari
Journal:  Stem Cell Rev Rep       Date:  2022-07-25       Impact factor: 6.692

4.  Leucocyte complement receptor 1 (CR1/CD35) transcript and its correlation with the clinical disease activity in rheumatoid arthritis patients.

Authors:  D Anand; U Kumar; M Kanjilal; S Kaur; N Das
Journal:  Clin Exp Immunol       Date:  2014-06       Impact factor: 4.330

5.  Antibody CR1-2B11 recognizes a non-polymorphic epitope of human CR1 (CD35).

Authors:  C-H Chen; I Ghiran; F J M Beurskens; G Weaver; J A Vincent; A Nicholson-Weller; L B Klickstein
Journal:  Clin Exp Immunol       Date:  2007-06       Impact factor: 4.330

Review 6.  All Things Complement.

Authors:  Joshua M Thurman; Carla M Nester
Journal:  Clin J Am Soc Nephrol       Date:  2016-06-23       Impact factor: 8.237

7.  Mesenchymal Stem Cells Control Complement C5 Activation by Factor H in Lupus Nephritis.

Authors:  Haijun Ma; Chang Liu; Bingyu Shi; Zhuoya Zhang; Ruihai Feng; Minghao Guo; Liwei Lu; Songtao Shi; Xiang Gao; Wanjun Chen; Lingyun Sun
Journal:  EBioMedicine       Date:  2018-06-07       Impact factor: 8.143

Review 8.  Deposition of the Membrane Attack Complex in Healthy and Diseased Human Kidneys.

Authors:  Jacob J E Koopman; Mieke F van Essen; Helmut G Rennke; Aiko P J de Vries; Cees van Kooten
Journal:  Front Immunol       Date:  2021-02-11       Impact factor: 7.561

Review 9.  Complement and systemic lupus erythematosus.

Authors:  Mark J Walport
Journal:  Arthritis Res       Date:  2002-05-09

Review 10.  Complement Receptor 1: disease associations and therapeutic implications.

Authors:  Rohan Khera; Nibhriti Das
Journal:  Mol Immunol       Date:  2008-11-11       Impact factor: 4.407

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.